Esprit BTK Post-Approval Study
a study on Chronic Limb-Threatening Ischemia
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCLA UCSF
- Dates
- study startedcompletion around
Description
Summary
The Esprit BTK PAS is a prospective, single-arm, multi-center observational study to assess the continued safety and effectiveness of the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System under commercial use, in patients with diseased infrapopliteal lesions causing CLTI (Chronic Limb-Threatening Ischemia) in a real-world setting. The clinical investigation will be conducted at up to 50 sites in the United States (US) and additional sites may be added outside of the US (OUS). Approximately 200 patients with a minimum of 50% of patients in the US will be registered in the clinical investigation.
Official Title
Esprit BTK Post-Approval Study (Esprit BTK PAS)
Keywords
Chronic Limb-Threatening Ischemia, ABT-CIP-10519, Esprit BTK System, Infrapopliteal lesions, Post-approval study
Eligibility
You can join if…
Open to people ages 18 years and up
- General Inclusion Criteria
- Subject must provide written informed consent prior to any study-specific procedures which are not considered standard of care at the site.
- Informed consent can be obtained up to 3 days post-procedure or prior to discharge whichever comes first.
- Subject, or a legally acceptable representative must provide written informed consent per site IRB/EC requirements.
- Subject must be at least 18 years of age.
- Subject has evidence of symptomatic Chronic Limb-Threatening Ischemia (CLTI) with infrapopliteal lesions.
- Subject must provide written informed consent prior to any study-specific procedures which are not considered standard of care at the site.
- Anatomic Inclusion Criteria
- Subjects who have lesion(s) in an infrapopliteal vessel with reference vessel diameter ≥ 2.5 mm and ≤ 4.0 mm.
- Target lesion(s) must have ≥ 70% stenosis, per visual assessment at the time of the procedure. If needed, quantitative imaging (angiography and intravascular imaging) can be used to aid accurate sizing of the vessels.
You CAN'T join if...
- General Exclusion Criteria
- Subjects who have contraindications to the Esprit BTK System per the instruction for use (IFU).
- Subject is currently participating in another clinical investigation.
- Subject is unable or unwilling to provide written consent prior to enrollment.
- Subject with life expectancy ≤ 1 year.
- Subject with an unsalvageable limb (as per physician assessment at the time of the index procedure), who is likely to get a below-the-knee amputation.
- Anatomic Exclusion Criteria
- Subject has in-stent restenosis in the target vessel or requires treatment with a metallic stent in the target vessel during the index procedure.
- Subject had been previously treated with Esprit BTK Scaffold(s).
Locations
- UCSF Fresno
accepting new patients
Fresno California 93701 United States - Ronald Reagan UCLA Medical Center
not yet accepting patients
Los Angeles California 90095 United States - Good Samaritan Hospital
not yet accepting patients
Los Angeles California 90017 United States - Hendrick Medical Center
accepting new patients
Abilene Texas 79601 United States
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Abbott Medical Devices
- ID
- NCT06656364
- Study Type
- Interventional
- Participants
- Expecting 200 study participants
- Last Updated